Amgen Inc. and its partner UCB SA reported that the sclerostin inhibitor romosozumab met its primary endpoint in a pivotal phase III study, called Bridge, providing men with osteoporosis with a statistically significant increase in bone mineral density (BMD) at the lumbar spine vs. placebo at 12 months.